Stocks · Healthcare · Biotechnology
Oramed Pharmaceuticals Inc. ORMP
$4.49 +0.22% Close, Oct 2, 2026 · NASDAQ · Market cap $183.8M
Inexpensive vs sectorLow risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The shares trade at 1.1× trailing earnings, lower than 88% of the company's own readings over the past five years.
- The stock is in an uptrend: above its 200-day average for 225 trading days, with the 50-day average above the 200-day.
- Over the past year the stock returned +76.1%, ahead of the S&P 500 by 61.0 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 2%
- Revenue growth, 3-year CAGRBottom 11%
- Revenue growth accelerationTop 46%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 36%
- Cash conversion (OCF / net income)Bottom 7%
- Accruals (lower is better)Bottom 2%
- Net debt / EBITDA (lower is better)Top 33%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 1%
- Free-cash-flow yieldTop 45%
- EBITDA / enterprise valueTop 1%
- P/E vs own 5-year history (lower is better)Top 27%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 18%
- 6-month returnTop 31%
- 1-year return vs S&P 500Top 20%
- Distance from 52-week highTop 28%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 4%
- Consecutive EPS beatsTop 25%
- Share of analysts rating BuyBottom 47%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 23%
- Maximum drawdown, 3 yearsTop 17%
- Beta vs S&P 500 (lower is better)Top 13%
- Net debt / EBITDA (lower is better)Top 33%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -100.0% | -100.0% | → |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -100.0% | -100.0% | → | Bottom 2% |
| Return on invested capital | -3.2% | — | Top 36% | |
| Revenue growth, 3-year CAGR | -9.6% | — | Bottom 11% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- -0.03×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 48.8%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.10×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.04%
- Net buyback yield (TTM)
- 2.40%
- Shareholder yield
- 2.44%
- Share count change, 1 year
- -0.3%
- Share count change, 3-year CAGR
- +1.9%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 10, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 3
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +100.0%
- Average 2-day reaction, last 8
- -1.3%
- Positive 20 days after report
- 6 of 8
Analysts
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 75%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 10, 2026 | +541.9% | -2.3% | +4.2% | +16.5% | — |
| May 19, 2026 | — | +0.9% | -5.8% | -12.1% | +2.1% |
| Mar 26, 2026 | +25.0% | -5.1% | -3.1% | +9.7% | +14.6% |
| Nov 13, 2025 | +2925.0% | -2.8% | +1.2% | +23.1% | +36.8% |
| Aug 14, 2025 | -25.0% | +0.0% | -2.4% | +14.6% | +3.8% |
| May 15, 2025 | -533.3% | -0.5% | -4.5% | +1.4% | -5.4% |
| Mar 27, 2025 | +133.3% | -2.5% | -6.8% | -2.5% | -10.6% |
| Nov 7, 2024 | -9695.9% | +1.7% | -0.9% | +7.3% | -6.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 10, 2026 | $2.76 | $0.43 | +541.9% | — |
| May 19, 2026 | $0.91 | — | — | — |
| Mar 26, 2026 | -$0.06 | -$0.08 | +25.0% | — |
| Nov 13, 2025 | $1.13 | -$0.04 | +2925.0% | — |
| Aug 14, 2025 | -$0.05 | -$0.04 | -25.0% | — |
| May 15, 2025 | -$0.19 | -$0.03 | -533.3% | $2.0M |
| Mar 27, 2025 | $0.01 | -$0.03 | +133.3% | — |
| Nov 7, 2024 | -$0.48 | -$0.00 | -9695.9% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 1.1× | 3.4× | 13th | Top 1% |
| P/E (forward) | 1.0× | — | — | — |
| EV / EBITDA | 1.1× | — | — | Top 1% |
| Free-cash-flow yield | -2.92% | — | — | Top 45% |
| Earnings yield | 91.54% | — | — | Top 1% |
P/E over the past five years
Range 1.0× – 21.6× since Dec 31, 2023. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 225
- 50-day average slope (20 days)
- +3.7%
- 200-day average slope (20 days)
- +5.3%
- Distance from 50-day average
- -2.9%
- Distance from 200-day average
- +14.5%
- RSI (14)
- 39.3
- Relative volume
- 0.94×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 41.0%
- Volatility vs own 5-year history
- 10th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.42
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -15.9%
- Maximum drawdown, 3 years
- -44.1%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Nov 8, 2021 | Nov 1, 2023 | -94.3% | 498 days | Not yet recovered |
| Feb 17, 2021 | Mar 4, 2021 | -33.7% | 11 days | 59 days (May 27, 2021) |
| Aug 10, 2021 | Aug 19, 2021 | -32.8% | 7 days | 24 days (Sep 23, 2021) |
| Nov 27, 2020 | Dec 1, 2020 | -17.3% | 2 days | 7 days (Dec 10, 2020) |
| Jun 9, 2021 | Jul 7, 2021 | -16.9% | 19 days | 13 days (Jul 26, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $183.8M
- P/E (TTM)
- 1.1
- EPS, diluted (TTM)
- $4.11
- Revenue (TTM)
- $0
- Dividend yield
- 5.57%
- 52-week range
- $2.09 – $5.47
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.7M | $2.7M | $1.3M | $0 | $2.0M |
| Gross profit | $2.7M | $2.7M | $1.3M | $0 | $13,000 |
| Operating income | -$24.2M | -$40.6M | -$15.8M | -$12.8M | -$15.1M |
| Net income | -$22.2M | -$37.8M | $5.5M | -$19.1M | $64.0M |
| EPS (diluted) | -$0.78 | -$0.97 | $0.14 | -$0.48 | $1.50 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $2.0M | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.6M | -$10.2M | -$7.6M | $13.3M | $48.4M | $10.0M | $38.3M | $78.2M |
| EPS (diluted) | -$0.48 | -$0.26 | -$0.19 | $0.31 | $1.13 | $0.23 | $0.91 | $1.84 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$21.2M | -$28.7M | -$10.3M | -$8.4M | -$9.1M |
| Capital expenditure | -$374,999 | -$495,999 | -$253,999 | -$17,999 | -$1.9M |
| Free cash flow | -$21.6M | -$29.2M | -$10.5M | -$8.4M | -$11.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $101.4M | $11.6M | $2.4M | -$2.5M | -$4.7M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $50.6M
- Total assets
- $369.6M
- Total liabilities
- $52.2M
- Total debt
- $733,000
- Net debt
- -$14.5M
- Shareholders’ equity
- $317.5M
As of Jun 30, 2026 (filed Aug 10, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jan 16, 2026 | $0.25 | Jan 26, 2026 |
Short interest
- Shares sold short
- 1,307,745
- Days to cover
- 7.43
- Change vs previous report
- +13.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Jan 23, 2013
- 1-for-12
- Jun 14, 2004
- 33-for-10